Skip to content

Join Us
Members Area

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Publication Category: Medications

Community pharmacists’ experiences and perspectives on GLP-1 receptor agonists for obesity management: a cross-sectional study in Ireland

Demmel J, Farrell C, Timon CM, Cleary O, Christie HL, O'Leary N, George CV, Dunne P, Mitchell S, le Roux CW, O'Hara C, Flood M, Flynn AC. Community pharmacists’ experiences and perspectives on GLP-1 receptor agonists for obesity management: a cross-sectional study in Ireland Int J Pharm Pract

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, Zhang H, Gao Y, Khunti K, Le Roux CW, Widyahening IS, Fan Q, Liu T, Mao Y, Florez ID, Du H, Pan X, Zou X, Wang C, Sun X, Li J, Hao Q, Jia Q, Sun F, Zhu Z, Agoritsas T, Tian H, Vandvik PO, Li S. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis BMJ

A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model

Liu Y, Liu X. A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model Biomed Pharmacother

Obesity Remission: A Missing Target in Contemporary Medicine

Koufakis T, Kokkinos A, Busetto L, le Roux CW. Obesity Remission: A Missing Target in Contemporary Medicine Obes Rev

GLP-1 receptor agonists and weight-loss strategies for individuals with obesity and hip or knee osteoarthritis: a scoping review

McCann C, Clement N, Murray A, Kearney R, Madigan S, Gee C, Walmsley P, Morrison S, Chopra S, Hall A. GLP-1 receptor agonists and weight-loss strategies for individuals with obesity and hip or knee osteoarthritis: a scoping review Br J Sports Med

How does survodutide work? Plain language review of a potential new medication for obesity and liver disease

Almandoz JP, Miras AD, Seufert J, Paul E. How does survodutide work? Plain language review of a potential new medication for obesity and liver disease Ther Adv Gastroenterol
MASLD

Survodutide Once Weekly for the Treatment of Adults with Obesity

le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Ekinci EI, Jastreboff AM, Ji L, Ogawa W, Pedersen SD, Pietiläinen KH, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M Survodutide Once Weekly for the Treatment of Adults with Obesity N Engl J Med

Redemptive narratives of remission: agency, free will and type 2 diabetes in the era of Ozempic

Murphy KF. Redemptive narratives of remission: agency, free will and type 2 diabetes in the era of Ozempic Med Humanit
Insulin Resistance & Diabetes

Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists

Temperley HC, Kelly ME. Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists J Clin Oncol

Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review

Mady R, Tafazal H, Soliman H, Ramadan A, Hajaj M. Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review Cureus

Older posts

Page1 Page2 … Page30 Next →

Search for:

Recent Posts

10th ASOI Annual Scientific Meeting 2026
9th ASOI Annual Conference – Registration now open!
Press Release for World Obesity Day 4th March 2024
ASOI and ICPO response to : Medical Council Communication: “Important medicine shortage information – Ozempic (semaglutide)”
Things to do in Dublin during ECO

ASOI

info@asoi.info

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Home
ASOI News
About Us
Events
Media Resources
Public Resources
Guidelines
Research

Privacy Policy
Site Map

©2026 ASOI